Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 May 3:15:1157818.
doi: 10.3389/fnagi.2023.1157818. eCollection 2023.

Role of piRNA biogenesis and its neuronal function in the development of neurodegenerative diseases

Affiliations
Review

Role of piRNA biogenesis and its neuronal function in the development of neurodegenerative diseases

Kaoru Sato et al. Front Aging Neurosci. .

Abstract

Neurodegenerative diseases, such as Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS), are caused by neuronal loss and dysfunction. Despite remarkable improvements in our understanding of these pathogeneses, serious worldwide problems with significant public health burdens are remained. Therefore, new efficient diagnostic and therapeutic strategies are urgently required. PIWI-interacting RNAs (piRNAs) are a major class of small non-coding RNAs that silence gene expression through transcriptional and post-transcriptional processes. Recent studies have demonstrated that piRNAs, originally found in the germ line, are also produced in non-gonadal somatic cells, including neurons, and further revealed the emerging roles of piRNAs, including their roles in neurodevelopment, aging, and neurodegenerative diseases. In this review, we aimed to summarize the current knowledge regarding the piRNA roles in the pathophysiology of neurodegenerative diseases. In this context, we first reviewed on recent updates on neuronal piRNA functions, including biogenesis, axon regeneration, behavior, and memory formation, in humans and mice. We also discuss the aberrant expression and dysregulation of neuronal piRNAs in neurodegenerative diseases, such as AD, PD, and ALS. Moreover, we review pioneering preclinical studies on piRNAs as biomarkers and therapeutic targets. Elucidation of the mechanisms underlying piRNA biogenesis and their functions in the brain would provide new perspectives for the clinical diagnosis and treatment of AD and various neurodegenerative diseases.

Keywords: PIWI; aging; biomarker; dementia; neurodegenerative disease; neuron; piRNA.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
piRNA-mediated regulation of gene expression. (A) The current model for piRNA-mediated RNA silencing mechanism. In the cytoplasm, piRNA guides PIWI protein to the complementary target RNA to catalyze the endonucleolytic cleavage (slicing). While, in the nucleus, PIWI-piRNA complexes recognize nascent RNAs and recruit epigenetic modifiers, such as DNA methyltransferases, histone modifiers, and chromatin mark readers, thereby modifying the chromatin state and gene expression. RNAPII, RNA polymerase II. (B) A gene regulation via piRNAs during neuronal differentiation of NT2 cells.

References

    1. Abdelhamid R. F., Ogawa K., Beck G., Ikenaka K., Takeuchi E., Yasumizu Y., et al. (2022). piRNA/PIWI protein complex as a potential biomarker in sporadic amyotrophic lateral sclerosis. Mol. Neurobiol. 59, 1693–1705. doi: 10.1007/s12035-021-02686-2, PMID: - DOI - PMC - PubMed
    1. Andrews P. W. (1984). Retinoic acid induces neuronal differentiation of a cloned human embryonal carcinoma cell line in vitro. Dev. Biol. 103, 285–293. doi: 10.1016/0012-1606(84)90316-6, PMID: - DOI - PubMed
    1. Aravin A., Gaidatzis D., Pfeffer S., Lagos-Quintana M., Landgraf P., Iovino N., et al. (2006). A novel class of small RNAs bind to MILI protein in mouse testes. Nature 442, 203–207. doi: 10.1038/nature04916 - DOI - PubMed
    1. Bartels A. L., Leenders K. L. (2010). Cyclooxygenase and neuroinflammation in Parkinson’s disease neurodegeneration. Curr. Neuropharmacol. 8, 62–68. doi: 10.2174/157015910790909485, PMID: - DOI - PMC - PubMed
    1. Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., Seitelberger F. (1973). Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J. Neurol. Sci. 20, 415–455. doi: 10.1016/0022-510x(73)90175-5, PMID: - DOI - PubMed